The Center for Healthcare Supply Chain Research recently released Assessing the Impact of Risk Evaluation and Mitigation Strategies (REMS) Requirements on the Pharmaceutical Supply Chain, the first comprehensive research study analyzing the impact of REMS programs across the healthcare supply chain. Produced in collaboration with Campbell Alliance Group, Inc., the study outlines the current REMS landscape, evaluates the impact of these requirements on key supply chain stakeholders, illustrates the challenges the industry faces, examines economic considerations, assesses two program case studies and highlights opportunities for future program enhancements. The research provides recommendations on how to improve REMS in the future, as well as insights that are helpful to anyone seeking to understand the potential impact of REMS on the pharmaceutical supply chain.
As of June 1, 2012, there were 94 pharmaceutical products that require Risk Evaluation and Mitigation Strategies (REMS). This number was 179 in March 2011, but from April 14, 2011 to the present date, FDA has ruled to remove several medications from their medication guide-only requirements and several other programs have had modifications in complexity.
To learn more about the impact of REMS on the supply chain, order the REMS publication today!
Read the press release
Read our article for APhA
Read our Pharmaceutical Commerce article
View the table of contents
Purchase your copy
Download an order form